Swept-source optical coherence tomography angiography for choroidal neovascularization after bevacizumab and photodynamic therapy

Jung, Jesse J.; Chen, Michael H.; Chung, Patty; Lee, Scott S.

doi:10.1016/j.ajoc.2016.01.002

Cited by 5 publications

(6 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Regarding PDT, to the best of our knowledge, few studies have used OCTA to longitudinally follow patients after PDT. Jung et al used OCTA to observe one case of AMD with types 1 and 2 CNV before and after PDT and anti-VEGF therapy (bevacizumab, Avastin, Genentech Inc.) and reported significant resolution of type 2 CNV and decreased flow and size of type 1 CNV 14 . The current results showed the time course of OCTA findings in three cases with type 1 CNV and two cases with PCV before and after PDT and IVA.…”

Section: Discussionmentioning

confidence: 48%

“…Jung et al used OCTA to observe one case of AMD with types 1 and 2 CNV before and after PDT and anti-VEGF therapy (bevacizumab, Avastin, Genentech Inc.) and reported significant resolution of type 2 CNV and decreased flow and size of type 1 CNV. 14 The current results showed the time course of OCTA findings in three cases with type 1 CNV and two cases with PCV before and after PDT and IVA. One month after treatment, the CNV signal decreased, and in two cases no CNV signal was seen on OCTA.…”

Section: Discussionmentioning

confidence: 55%

“…The technology shows the retinal vasculature in each retinal slab and the choriocapillaris in a separate en-face image. Some studies that used OCTA have described choriocapillaris flow after PDT,11, 12, 13 and Jung et al reported the swept-source (SS) OCTA findings in the first month after application of PDT 14 ; however, to the best of our knowledge, no report has described CNV remodeling after PDT with OCTA. In the current study, we retrospectively evaluated the time course of CNV remodeling after full-fluence PDT and intravitreal injections of aflibercept (IVA; Eylea, Bayer Yakuhin, Ltd., Osaka, Japan; Santen Pharmaceutical Co., Ltd., Osaka, Japan) for treating AMD.…”

Section: Introductionmentioning

confidence: 93%

See 2 more Smart Citations

Time course of swept-source optical coherence tomography angiography findings after photodynamic therapy and aflibercept in eyes with age-related macular degeneration

Sayanagi

Hara

Fukushima

et al. 2019

American Journal of Ophthalmology Case Reports

View full text Add to dashboard Cite

Purpose To report swept-source optical coherence tomography angiography (SS-OCTA) findings after full-fluence photodynamic therapy (PDT) and aflibercept intravitreal injection (IVA) for age-related macular degeneration (AMD). Methods Five eyes of five patients with AMD treated with PDT and IVA were include into the study. We retrospectively reviewed the data obtained from the five patients using SS-OCTA before and after treatment. Three eyes had type 1 choroidal neovascularization (CNV) and two eyes had polypoidal choroidal vasculopathy. Results Before treatment, the CNV signals detected in all cases, decreased in three eyes and were not detected completely in two eyes at 1 months after treatment. The areas indicating CNV increased over time, but they did not increase to the baseline level. No CNV signal was detected in one eye during follow-up. In all cases, the exudation unchanged or resolved without additional IVA; the exudation recurred in two cases. In one eye, the CNV signal and the exudation occurred simultaneously; however, there was no association in another eye. A feeder vessel, from which the CNV signal seemed to originate, was seen in one of the five eyes. Conclusion and Importance SS-OCTA is useful to monitor the morphology of CNV after PDT and IVA, indicating that the remodeling of the choroidal vasculature occurs gradually after treatment. The presence or absence of the CNV signal might indicate CNV activity.

show abstract

Section: Discussionmentioning

confidence: 48%

Section: Discussionmentioning

confidence: 55%

Section: Introductionmentioning

confidence: 93%

See 1 more Smart Citation

Time course of swept-source optical coherence tomography angiography findings after photodynamic therapy and aflibercept in eyes with age-related macular degeneration

Sayanagi

Hara

Fukushima

et al. 2019

American Journal of Ophthalmology Case Reports

View full text Add to dashboard Cite

show abstract

“…Finally, segmentation of SS-OCTA data into choroidal or CC en face slabs is showing promise for the detection of inflammatory disease activity without a need for fluorescein or indocyanine green based angiography. 15,[24][25][26][27] In order to bring these benefits of SS-OCTA imaging into more widespread clinical use, image acquisition will need to be coupled with automated image analysis for the rapid, reproducible, and quantitative detection of relevant disease associated abnormalities. Towards this goal, in this study, we test an automated en face CC OCTA image analysis approach for the ability to detect and quantify CC in patients with uveitis.…”

Section: Introductionmentioning

confidence: 99%

Quantitative Analysis of the Choriocapillaris in Uveitis Using En Face Swept-Source Optical Coherence Tomography Angiography

Chu

Weinstein

Wang

et al. 2020

American Journal of Ophthalmology

View full text Add to dashboard Cite

Purpose: To perform a quantitative analysis of choriocapillaris (CC) flow deficits (FDs) in patients with uveitis. Design: Retrospective cross-sectional studyMethods: Swept-source optical coherence tomography based angiography (SS-OCTA) macular volume scans (3×3 mm and 6×6 mm) were obtained using the PLEX® Elite 9000: En face CC images were generated and analyzed using an automated flow deficit identification algorithm. Three quantitative metrics were determined for each eye: FD number (FDN), mean FD size (MFDS), and FD density (FDD). Quantitative metrics were compared between uveitis and control eyes. The uveitis cohort was further subdivided by the presence or absence of choroidal involvement, and quantitative metrics were compared between subgroups and normal controls Results: A total of 38 eyes from 38 controls and 73 eyes from 73 uveitis subjects were included in this study. Eyes with uveitis have significantly larger CC MFDS (3×3 mm, p<0.0001; 6×6 mm, p<0.0001) and higher FDD (p=0.0002; p=0.0076) when compared to control eyes. Additional analysis determined that these differences are due to the choroidal disease subgroup, which demonstrates significantly larger MFDS (3×3 =1108 μm 2 ; 6×6 =1104 μm 2 ) compared to both normal controls (752 μm 2 , p<0.0001; 802 μm 2 , p<0.0001) and uveitis patients without choroidal involvement (785 μm 2 , p<0.0001; 821 μm 2 , p<0.0001). No significant differences were found between the quantitative metrics of controls and patients without choroidal involvement.Conclusions: Automated quantification of CC can identify pathological FDs and provide quantitative metrics describing such lesions in patients with uveitis. Posterior uveitis patients have significantly larger CC FDs than patients with other forms of uveitis.

show abstract

“…In addition, FA images in the later phases of the angiogram may exhibit leakage from CNV lesions, which may obscure the details of the vessels within it. 31 …”

Section: Introductionmentioning

confidence: 99%

Anti-vascular endothelial growth factor therapy for the treatment of myopic choroidal neovascularization

Tan¹,

Sadda²

2017

OPTH

View full text Add to dashboard Cite

Myopic choroidal neovascularization (CNV) is a sight-threatening condition which occurs in eyes with myopia, particularly in those with pathologic myopia. It is the most common cause of CNV among patients younger than 50 years. Hemorrhage and exudation from the CNV lesion may eventually result in scarring or chorioretinal atrophy. While myopic CNV was previously treated with focal laser photocoagulation or photodynamic therapy (PDT), the current treatment of choice is anti-vascular endothelial growth factor (VEGF) agents. Many studies have demonstrated the efficacy of intravitreal anti-VEGF agents in the treatment of myopic CNV. The RADIANCE study reported that intravitreal ranibizumab was superior to PDT in eyes with myopic CNV (at 3 months, both groups receiving intravitreal ranibizumab gained 10.5 and 10.6 letters vs 2.2 letters among patients receiving PDT). In addition, the study demonstrated similar visual outcomes in eyes treated on the basis of visual acuity stabilization or disease activity criteria. Other clinical studies have provided evidence for the efficacy of ranibizumab and aflibercept in the treatment of myopic CNV. This review addresses the epidemiology, pathophysiology, and imaging characteristics of myopic CNV, and discusses the evidence for the efficacy of anti-VEGF agents as compared to laser photocoagulation and PDT.

show abstract

Swept-source optical coherence tomography angiography for choroidal neovascularization after bevacizumab and photodynamic therapy

Cited by 5 publications

References 12 publications

Time course of swept-source optical coherence tomography angiography findings after photodynamic therapy and aflibercept in eyes with age-related macular degeneration

Time course of swept-source optical coherence tomography angiography findings after photodynamic therapy and aflibercept in eyes with age-related macular degeneration

Quantitative Analysis of the Choriocapillaris in Uveitis Using En Face Swept-Source Optical Coherence Tomography Angiography

Anti-vascular endothelial growth factor therapy for the treatment of myopic choroidal neovascularization

Contact Info

Product

Resources

About